Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 4
2014 4
2015 6
2016 7
2017 15
2018 15
2019 3
2020 5
2021 5
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Sirukumab: A Potential Treatment for Mood Disorders?
Zhou AJ, Lee Y, Salvadore G, Hsu B, Fonseka TM, Kennedy SH, McIntyre RS. Zhou AJ, et al. Adv Ther. 2017 Jan;34(1):78-90. doi: 10.1007/s12325-016-0455-x. Epub 2016 Dec 2. Adv Ther. 2017. PMID: 27913990 Free PMC article. Review.
A PubMed/Medline database search was performed using the following search terms: sirukumab; anti-IL-6; IL-6; major depressive disorder; inflammation. ...We suggest that sirukumab represents a prototype and possibly a proof-of-concept that agents that engage IL-6 tar …
A PubMed/Medline database search was performed using the following search terms: sirukumab; anti-IL-6; IL-6; major depressive disorde …
Sirukumab : a novel therapy for lupus nephritis?
Thanarajasingam U, Niewold TB. Thanarajasingam U, et al. Expert Opin Investig Drugs. 2014 Oct;23(10):1449-55. doi: 10.1517/13543784.2014.950837. Epub 2014 Sep 5. Expert Opin Investig Drugs. 2014. PMID: 25189410 Review.
Their review focuses on the available data on the use of sirukumab in patients. Data from Phase I trials would indicate that sirukumab is generally safe and well tolerated. ...However, the clinical efficacy of sirukumab in SLE and LN, in particular, remains t …
Their review focuses on the available data on the use of sirukumab in patients. Data from Phase I trials would indicate that siruk …
Sirukumab: a promising therapy for rheumatoid arthritis.
Pelechas E, Voulgari PV, Drosos AA. Pelechas E, et al. Expert Opin Biol Ther. 2017 Jun;17(6):755-763. doi: 10.1080/14712598.2017.1315099. Epub 2017 Apr 10. Expert Opin Biol Ther. 2017. PMID: 28374627
Interleukin-6 (IL-6) wields pleiotropic biological effects that are crucially implicated in the activation of acute inflammatory response. Sirukumab is a monoclonal antibody with high affinity for IL-6. Areas covered: In this review, the authors examine sirukumab as …
Interleukin-6 (IL-6) wields pleiotropic biological effects that are crucially implicated in the activation of acute inflammatory response. …
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP. Takeuchi T, et al. Ann Rheum Dis. 2017 Dec;76(12):2001-2008. doi: 10.1136/annrheumdis-2017-211328. Epub 2017 Aug 30. Ann Rheum Dis. 2017. PMID: 28855173 Free PMC article. Clinical Trial.
OBJECTIVES: Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. ...METHODS: Patients were randomised 1:1:1 to treatment with …
OBJECTIVES: Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab …
Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018.
Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE. Bartoli F, et al. Expert Rev Clin Immunol. 2018 Jul;14(7):539-547. doi: 10.1080/1744666X.2018.1487291. Epub 2018 Jul 4. Expert Rev Clin Immunol. 2018. PMID: 29925278 Review.
Tocilizumab (TCZ) is now widely used in patients with active RA and a number of additional agents that target the IL-6 pathways are under development, including sirukumab (SRK). Areas covered: SRK is an IgG1kappa human anti-IL-6 monoclonal antibody which binds to IL-6 and …
Tocilizumab (TCZ) is now widely used in patients with active RA and a number of additional agents that target the IL-6 pathways are under de …
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.
Lazzerini PE, Capecchi PL, Guidelli GM, Selvi E, Acampa M, Laghi-Pasini F. Lazzerini PE, et al. Drug Des Devel Ther. 2016 Sep 26;10:3083-3098. doi: 10.2147/DDDT.S99898. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27713619 Free PMC article. Review.
These successful results have encouraged the development of novel IL-6 inhibitors, among which a promising agent is sirukumab (SRK), a human anti-IL-6 monoclonal antibody currently under evaluation in Phase II/III studies in patients with RA, systemic lupus erythematosus, …
These successful results have encouraged the development of novel IL-6 inhibitors, among which a promising agent is sirukumab (SRK), …
Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study.
Thorne C, Takeuchi T, Karpouzas GA, Sheng S, Kurrasch R, Fei K, Hsu B. Thorne C, et al. RMD Open. 2018 Nov 16;4(2):e000731. doi: 10.1136/rmdopen-2018-000731. eCollection 2018. RMD Open. 2018. PMID: 30564449 Free PMC article.
METHODS: Patients were randomised 1:1:1 to sirukumab 100 mg every 2 weeks (q2w), 50 mg every 4 weeks or placebo q2w subcutaneously. ...The safety profile of sirukumab was as expected for an anti-IL-6 agent, with no new signals reported....
METHODS: Patients were randomised 1:1:1 to sirukumab 100 mg every 2 weeks (q2w), 50 mg every 4 weeks or placebo q2w subcutaneously. . …
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, Tanaka Y. Takeuchi T, et al. Arthritis Res Ther. 2018 Mar 7;20(1):42. doi: 10.1186/s13075-018-1536-9. Arthritis Res Ther. 2018. PMID: 29514712 Free PMC article. Clinical Trial.
BACKGROUND: Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The present study evaluated the safety and efficacy of …
BACKGROUND: Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy i …
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Smolen JS, et al. Ann Rheum Dis. 2014 Sep;73(9):1616-25. doi: 10.1136/annrheumdis-2013-205137. Epub 2014 Apr 3. Ann Rheum Dis. 2014. PMID: 24699939 Free PMC article. Clinical Trial.
In Part B (dose finding), 151 patients were randomised to sirukumab (100 mg q2w, 100 mg q4w, 50 mg q4w, or 25 mg q4w) through week 24, or placebo through week 10 with crossover to sirukumab 100 mg q2w (weeks 12-24). ...Infections were the most common type of AE; one …
In Part B (dose finding), 151 patients were randomised to sirukumab (100 mg q2w, 100 mg q4w, 50 mg q4w, or 25 mg q4w) through week 24 …
65 results

Searches related to "sirukumab"